Drug Details
| General Information of the Drug (ID: DR1922) | ||||
|---|---|---|---|---|
| Name |
Proanthocyanidins
|
|||
| Synonyms |
ZINC584567037; N1697
Click to Show/Hide
|
|||
| Molecular Type |
Small molecule
|
|||
| Disease | Atherosclerosis [ICD-11: BD40] | Phase 2 | [1] | |
| Structure |
|
Click to Download Mol2D MOL |
||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | ||||
| Formula |
C30H26O13
|
|||
| PubChem CID | ||||
| Canonical SMILES |
C1C(C(OC2=CC(=CC(=C21)O)O)C3=CC(=C(C=C3)O)O)OC4(C(C(C5=C(C=C(C=C5O4)O)O)O)O)C6=CC(=C(C=C6)O)O
|
|||
| InChI |
1S/C30H26O13/c31-14-7-19(35)16-11-25(28(41-23(16)9-14)12-1-3-17(33)20(36)5-12)43-30(13-2-4-18(34)21(37)6-13)29(40)27(39)26-22(38)8-15(32)10-24(26)42-30/h1-10,25,27-29,31-40H,11H2/t25-,27+,28+,29-,30+/m1/s1
|
|||
| InChIKey |
HGVVOUNEGQIPMS-JOFXVPDFSA-N
|
|||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
| Omega-3 PUFAs | phytoplankton environmental sample | Click to Show/Hide the Molecular Data of This NP | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Biological
Regulation |
Down-regulation | Bifidobacterium secretion | ||||
| Up-regulation | Lactobacillus secretion | |||||
| In-vivo Model | A total of twenty-eight female Wistar-Kyoto rats aged 8-10 weeks were used in this study. | |||||
| Experimental
Result(s) |
Combined supplementation of Omega-3 PUFAs and proanthocyanidins from grape seed counteracts the effects of the Omega-3 PUFAs on health-promoting lactobacillus and bifidobacterium, and on acetic acid, while maintaining their beneficial effects on cholesterolemia. | |||||
| Target and Pathway | ||||
|---|---|---|---|---|
| Target(s) | C-C chemokine receptor type 2 (CCR2) | Molecule Info | [3] | |
| C-C chemokine receptor type 3 (CCR3) | Molecule Info | [3] | ||
| C-C chemokine receptor type 5 (CCR5) | Molecule Info | [3] | ||
| KEGG Pathway | Cytokine-cytokine receptor interaction | Click to Show/Hide | ||
| 2 | Chemokine signaling pathway | |||
| 3 | Endocytosis | |||
| 4 | Toxoplasmosis | |||
| 5 | Viral carcinogenesis | |||
| NetPath Pathway | TCR Signaling Pathway | Click to Show/Hide | ||
| 2 | IL2 Signaling Pathway | |||
| 3 | TGF_beta_Receptor Signaling Pathway | |||
| 4 | Leptin Signaling Pathway | |||
| 5 | RANKL Signaling Pathway | |||
| 6 | IL3 Signaling Pathway | |||
| 7 | TSLP Signaling Pathway | |||
| Panther Pathway | Inflammation mediated by chemokine and cytokine signaling pathway | Click to Show/Hide | ||
| Pathway Interaction Database | IL12-mediated signaling events | Click to Show/Hide | ||
| Reactome | Beta defensins | Click to Show/Hide | ||
| 2 | Chemokine receptors bind chemokines | |||
| 3 | G alpha (i) signalling events | |||
| 4 | Binding and entry of HIV virion | |||
| WikiPathways | GPCRs, Class A Rhodopsin-like | Click to Show/Hide | ||
| 2 | Defensins | |||
| 3 | Spinal Cord Injury | |||
| 4 | Peptide GPCRs | |||
| 5 | GPCR ligand binding | |||
| 6 | GPCR downstream signaling | |||
| 7 | TCR Signaling Pathway | |||
| 8 | HIV Life Cycle | |||
| 9 | GPCRs, Other | |||
